DNA methylation meningioma biomarkers: attributes and limitations
Z Li, Y Gao, J Zhang, L Han, H Zhao - Frontiers in Molecular …, 2023 - frontiersin.org
Meningioma, one of the most common primary central nervous system tumors, are classified
into three grades by the World Health Organization (WHO) based on histopathology. The …
into three grades by the World Health Organization (WHO) based on histopathology. The …
Clinical significance of molecular alterations and systemic therapy for meningiomas: where do we stand?
Simple Summary Meningiomas are the most frequent intracranial tumors and comprise a
heterogeneous spectrum of diseases, ranging from small, asymptomatic tumors that do not …
heterogeneous spectrum of diseases, ranging from small, asymptomatic tumors that do not …
Molecular neuropathology: an essential and evolving toolbox for the diagnosis and clinical management of central nervous system tumors
Molecular profiling has transformed the diagnostic workflow of CNS tumors during the last
years. The latest WHO classification of CNS tumors (5th edition), published in 2021, pushed …
years. The latest WHO classification of CNS tumors (5th edition), published in 2021, pushed …
Update on the diagnosis and management of meningiomas
F Maiuri, M Del Basso de Caro - Cancers, 2023 - mdpi.com
This series of five articles (one original article and four reviews) focuses on the most recent
and interesting research studies on the biomolecular and radiological diagnosis and the …
and interesting research studies on the biomolecular and radiological diagnosis and the …
Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data
LR Jensen, AD Maier, A Lomstein, T Graillon… - Neurosurgical …, 2022 - Springer
Abstract Treatment-refractory meningiomas have a dismal prognosis and limited treatment
options. Meningiomas express high-densities of somatostatin receptors (SSTR), thus …
options. Meningiomas express high-densities of somatostatin receptors (SSTR), thus …
Molecular landscapes of longitudinal NF2/22q and non‐NF2/22q meningiomas show different life histories
HK Ng, KKW Li, NYF Chung, JYT Chan… - Brain …, 2023 - Wiley Online Library
Recurrence is a major complication of some meningiomas. Although there were many
studies on biomarkers associated with higher grades or increased aggressiveness, few …
studies on biomarkers associated with higher grades or increased aggressiveness, few …
Pathology of the Tumors of the Central Nervous System
R Bumci, I Parthymos, C Zamboglou… - Intraoperative Flow …, 2023 - Springer
Up until the fourth edition of World Health Organization (WHO) Classification of Central
Nervous System (CNS) Tumors which was published in 2016, definitions of the tumor …
Nervous System (CNS) Tumors which was published in 2016, definitions of the tumor …
Biomolecular-Related Medical Therapy for Meningiomas
A Pellerino, F Bruno, E Pronello, R Rudà… - … : From Pathology to …, 2024 - Springer
Patients with progressive or recurrent meningiomas failing all surgical and radiotherapeutic
treatment options or patients with meningiomas in surgically challenging areas, such as the …
treatment options or patients with meningiomas in surgically challenging areas, such as the …
GAB1 as a Marker of Recurrence in Anterior Skull Base Meningioma
BACKGROUND: About one-third of anterior skull base meningiomas show Hedgehog
pathway activation. We have recently identified GAB1 as a surrogate marker for Hedgehog …
pathway activation. We have recently identified GAB1 as a surrogate marker for Hedgehog …
Comprehensive Overview of Genetic Alterations in Meningioma
Meningiomas are the most common intracranial tumors in adult patients. According to the
World Health Organization (WHO) criteria, meningiomas are classified into grades 1 to 3 for …
World Health Organization (WHO) criteria, meningiomas are classified into grades 1 to 3 for …